Welcome to our dedicated page for Hydreight Tech news (Ticker: HYDTF), a resource for investors and traders seeking the latest updates and insights on Hydreight Tech stock.
Hydreight Technologies Inc. reports on a U.S.-focused digital health infrastructure business that combines telehealth, pharmacy fulfillment, clinical coverage and on-demand healthcare services. Company news commonly covers financial results, platform operating leverage, product-order activity, partner onboarding and expansion of the VSDHOne direct-to-consumer platform.
Recurring developments also include new healthcare service categories, such as at-home STI pre-screening, updates on platform licenses and modular workflow capabilities, revenue guidance, profitability commentary and capital actions such as normal course issuer bid activity.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) has announced a strategic partnership with The DRIPBaR to launch 'DRIPBaR Direct,' a nationwide direct-to-consumer healthcare initiative. The service will be powered by Hydreight's VSDHOne platform, enabling The DRIPBaR to expand its IV therapy and wellness services across the United States.
The partnership follows a successful pilot phase that demonstrated increased client engagement and operational efficiency. Through the VSDHOne platform, clients can submit health information online, connect with licensed medical professionals remotely, and receive physician-prescribed wellness treatments for self-administration at home.
This collaboration combines Hydreight's mobile clinical network, which operates across 50 states, with The DRIPBaR's expertise in preventive healthcare and IV therapy solutions. The initiative aims to enhance accessibility to personalized health and wellness services, allowing The DRIPBaR to scale its digital health offerings to all franchise locations.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) and Victory Square have announced a $10 million D2C Digital Health Accelerator program through their VSDHOne platform. The initiative aims to support emerging healthcare brands across the United States by providing funding, resources, and platform access.
The program targets companies offering various treatments including skincare, hair loss, sexual health, weight management, and longevity solutions. To qualify, companies must have minimum revenue of $750,000 USD in the last 12 months, US-based operations, and commit to migrating to the VSDHOne platform.
Selected companies will receive funding through a combination of services, cash, and stock, along with access to VSDHOne's telehealth infrastructure, e-commerce solutions, nationwide compliance, marketing support, and a network of healthcare professionals. The initiative addresses inefficiencies in the US healthcare system, projected to reach $7.2 trillion by 2031.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) reported significant achievements in 2024, including the successful launch of VSDHOne, a telemedicine platform now operating in all 50 states with over 200 licenses sold. The company achieved record financial performance with $6.12 million in Q3 2024 revenue, representing a 54% year-over-year increase, and reached positive adjusted EBITDA.
The company reported $16.58 million in topline revenue for the first 9 months of 2024, a 37% increase compared to 2023. Hydreight was ranked 56th on Deloitte's Technology Fast 500™ in North America and 9th on Deloitte Canada's Technology Fast 50™.
For 2025, Hydreight plans to expand its platform by introducing comprehensive at-home testing services, driving organic growth through strategic acquisitions, and investing in technology partnerships. The company aims to address inefficiencies in the $4.9 trillion U.S. healthcare market through its national network of physicians, nurses, pharmacies, and compliance technology.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) has launched VSDHOne, a comprehensive Direct-to-Consumer healthcare platform now operational across all 50 U.S. states. The platform enables businesses to create their own healthcare brands with features including telemedicine technology, nationwide doctor networks, pharmacy fulfillment, and medical direction.
VSDHOne currently offers approximately 40 products across categories including skincare, hair loss, sexual health, hormone replacement therapy, and GLP-1 weight management. The platform operates on a SaaS model, with customers purchasing state-specific licenses and paying per-order fees. Since its Q2 2024 soft launch, VSDHOne has onboarded over 200 licenses and projects to reach 1,000 licenses by December 2025, with each license expected to process 5-20 orders daily.
Hydreight Technologies reported strong Q3 2024 financial results with record topline revenue of $6.12M, marking a 54% increase year-over-year. The company achieved positive Adjusted EBITDA of $48K compared to ($265K) in Q3 2023. GAAP revenue reached $4.53M, up 47% from Q3 2023, with gross margins of $1.53M. The company launched VSDHOne, a telemedicine solution, selling over 200 licenses across 50 states in its first 90 days. Hydreight was ranked 56th on Deloitte's Technology Fast 500™ and 9th in Canada's Fast 50 Program for 2024.
Hydreight Technologies has achieved significant recognition in Deloitte's prestigious technology rankings for 2024, securing the 56th position in North America's Technology Fast 500™ and ranking 9th in Canada's Technology Fast 50. The rankings showcase North America's fastest-growing companies across technology, media, telecommunications, life sciences, fintech, and energy tech sectors. Companies on the 2024 Technology Fast 500™ list demonstrated revenue growth ranging from 201% to 186,373% over three years, with average and median growth rates of 2,100% and 460% respectively. To qualify, companies must have proprietary technology, minimum operating revenues of US$50,000 in the base year and US$5 million in the current year.
Hydreight Technologies has secured the 9th position in Deloitte's 2024 Technology Fast 50™ awards program, recognizing Canada's fastest-growing technology companies based on revenue growth from 2020 to 2023. As a mobile clinical network and medical platform, Hydreight's achievement highlights its significant organic revenue growth and market position. The company, which was previously named one of Canada's Companies-to-Watch in the same program last year, qualified by meeting criteria including minimum revenue requirements of $50,000 in 2020 and $5 million in 2023, proprietary technology ownership, and investing at least 5% of gross revenues in R&D activities in Canada.
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) has expanded its VSDHOne platform to include Asynchronous Telehealth Treatments for skincare, hair loss, and sexual health. This addition allows patients to submit information anytime without requiring real-time consultations. The platform, launched in Q2 2024 with Victory Square Technologies, initially focused on Synchronous Telehealth treatments including GLP-1 and Testosterone Replacement Therapy. Within its first 90 days, VSDHOne sold over 200 licenses across all 50 states. The platform offers businesses a complete solution for launching direct-to-consumer healthcare brands, including compliance, telemedicine technology, and nationwide doctor and pharmacy networks.
Hydreight Technologies Inc. (TSXV: NURS, OTCQB: HYDTF) reported significant growth in Q2 2024:
- Record topline revenue of $10.46M in the first 6 months of 2024 (29% YOY increase)
- Q2 2024 GAAP revenue of $4.10M (52% increase from Q2 2023)
- Positive Adjusted EBITDA of $218K in Q2 2024
The company launched VSDHOne, a telemedicine and e-commerce solution, selling over 200 licenses across 50 states in 90 days. Hydreight secured national medical spa partners with almost 700 locations sold and 186 opened across the US. The company's platform facilitates mobile medical services, connecting healthcare providers with patients across all 50 states. Hydreight announced a Normal Course Issuer Bid and signed a partnership for US government agency contracts.
Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE:SO6), a mobile clinical network and medical platform operating across 50 U.S. states, has announced its intention to initiate a normal course issuer bid (NCIB). The company plans to repurchase up to 1,378,633 of its common shares, representing approximately 3.42% of outstanding shares and 10% of its public float.
The NCIB will commence on October 4, 2024, and conclude on October 3, 2025, unless completed earlier. Research Capital will conduct the bid on behalf of Hydreight. Purchases will be made on the open market through the TSX Venture Exchange, with the company paying the prevailing market price at the time of purchase. The repurchase will be funded from existing working capital.
Hydreight believes this move may contribute to an orderly market and is in the best interests of the company and its shareholders. The company may purchase shares if it believes they are trading at a price that doesn't adequately reflect Hydreight's business prospects, growth, and financial position.